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288 A.H. Al-jedai et al.ications, 73% were assigned category risk C, 10 medications (11%) were assigned category risk D,
and 12 medications (13%) were assigned category risk B. Only three medications were judged to be
safe during pregnancy based on the available evidence and were assigned category risk A. Inconsis-
tencies in deﬁning and reporting the foetal risk category among different drug regulatory authorities
could create confusion and affect prescribing. We believe that standardization and inclusion of this
information in the medication package insert is extremely important to all health care practitioners.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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In the United States, there are almost six million pregnancies
annually. On average, pregnant woman take three to ﬁve pre-
scription medications during pregnancy. For pregnant women
with chronic medical conditions, prescription medications
might need to be continued during pregnancy (Meadows,
2001). In Saudi Arabia and several other countries in the
world, there is no readily available risk categorization that
could guide medication prescribing during pregnancy (MOH
health statistics book for 2008).
In one report, approximately 2–4% of newly born babies
have some form of birth defects. Less than 1% is thought to
be linked to exposure to medications during pregnancy. About
9% are thought to be related to maternal medical conditions
while 20–25% apparently have a genetic basis. In general,
about 65% of birth defects are of unknown origin (Webster
and Freeman, 2001).
In another study, pregnant women who were exposed to
medications not considered teratogenic believed that their risk
for major malformations was 24% (Doering et al., 2002).
These suspicions are fed by the thalidomide disaster back in
the 1950s and 1960s. Many babies were born with severe upper
and lower limb deformities to women who used thalidomide to
treat pregnancy related nausea and vomiting. In the wake of
thalidomide disaster, the US-FDA established strict criteria
for approval of new medications, in addition to development
of the pregnancy risk classiﬁcation system in 1979 (Doering
et al., 2002). Several criticisms have been cited by experts when
this system was applied to practice such as being confusing,
primitive, and outdated. In December 2009, the US-FDA re-
leased a proposal to the public to amend its regulations per-
taining to the risk description in products labelling during
pregnancy and lactation that may eliminate the risk categori-
zation and add more details on the foetal and mother risk
(http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
DevelopmentResources/Labeling/ucm093310.htm). However,
until the writing of this manuscript, the US-FDA continues
to require risk categorization for newly approved medicationsand it is not clear whether this proposal will be approved with-
out changes and if the risk categorization will be removed.
This proposal was published in the public domain for the pub-
lic and health care professionals to submit their comments to
the US-FDA. Thus, the proposal may potentially receive sev-
eral changes to its contents before it gets approved and be-
comes a regulation. Despite this, the current US-FDA
regulations still require pregnancy risk categorization for the
newly approved medications. For example, in January 2012,
the US-FDA approved Ivacaftor (Kalydeco) for Cystic
Fibrosis and assigned it a pregnancy risk category B. Further-
more, the US-FDA and even after its proposal in 2009 contin-
ues to change pregnancy risk categorization of previously
marketed medications once new data are available. For exam-
ple, topiramate pregnancy risk categorization was recently
changed from C to D based on new evidence.
The US-FDA pregnancy risk categorization is the most
widely used method of classiﬁcation for medication use during
pregnancy in Saudi Arabia. Other international categorization
systems include the Australian pregnancy risk classiﬁcation
(Australian Drug Evaluation Committee Category), the Swed-
ish Catalogue of Approved Drugs (FASS), and the German
categorization system. To our knowledge, other national drug
regulatory authorities do not have an ofﬁcial pregnancy risk
categorization system. More than 100 medications available
in Europe, Canada, Australasia and the Middle East are not
currently approved by the US-FDA and hence do not have a
pregnancy risk categorization. Most practitioners believe that
the availability of pregnancy risk categorization is extremely
important to the health care practitioner when prescribing, dis-
pensing, or administering medications to pregnant women.
The aim of this review is to evaluate the foetal risk associ-
ated with non-US-FDA approved medications currently regis-
tered by the Saudi Food and Drug Authority (S-FDA). The
medications will be further categorized according to the US-
FDA pregnancy risk categorization system based on the avail-
able literature. It is important to note that the proposed risk
categorization is neither ofﬁcial nor is endorsed by the US-
FDA and it is solely based on expert opinion.
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We identiﬁed all non-US-FDAapprovedmedications registered
in the Saudi National Formulary (SNF) by the S-FDA as of
October 2007. These medications are also approved by other
drug regulatory authorities, including Canada, Europe, and
Australia but are not assigned a pregnancy risk category. A total
of 114 medications were identiﬁed of which 93 were considered
eligible for evaluation. The criterion for inclusion was any med-
ication not approved by US-FDA. Twenty-one medications
were excluded for different reasons, e.g., herbal products, med-
ications withdrawn from the market, or medications for veteri-
nary use only. A thorough literature evaluation was performed
to identify any associated risk with the use of the previously
identiﬁedmedications during any stage of pregnancy. Evaluated
outcomes included any functional or anatomical birth, orFigure 1 Proposed pregnancy r
Table 1 US-FDA pregnancy risk category deﬁnitions.
Category Description
A Controlled clinical trials in females failed to show a risk
foetus appears remote
B Either animal studies did not show a risk to the foetus
showed an adverse eﬀect on the foetus but well-controll
to the foetus
C Animal studies have shown teratogenic or embryocidal
studies are available in either animals or humans
D Positive evidence of foetal risk exists in humans, but be
risks (e.g., life-threatening situations or in cases where s
diseases)
X Studies in animals or humans have shown foetal abnorm
risk outweighs any possible beneﬁtembryocidal effects. Both immediate and delayed effects were
considered for this review. Effects on fertility were excluded.
Three clinical pharmacists (the authors of this manuscript)
recommended a US-FDA pregnancy risk category (Table 1)
for each medication after reviewing all available literature. An
algorithm was developed based on the US-FDA categorization
(Fig. 1). A literature search was performed to retrieve data using
different databases and drug information resources including
manufacturer package inserts using the Saudi Package Drug In-
sert (SPDI) (Saudi Food and Drug Authority. SPDI, 2008),
Electronic Medicines Compendium (EMC) (Available at:
http://emc.medicines.org.uk/),Medicines andHealthcare Prod-
ucts Regulatory Agency (MHRA) (Available at: http://
www.mhra.gov.uk/index.htm.AccessedAugust 26), BritishNa-
tional Formulary (BNF) (2007), International Lexi-CompDrug
Information Hand Book (Available at: http://online.lexi.com/isk categorization algorithm.
to the foetus in the ﬁrst trimester, and the possibility of harm to the
and no controlled human studies are available, or animal studies
ed clinical trials in pregnant females have failed to demonstrate a risk
eﬀects, but there are no controlled clinical trials in females, or no
neﬁts in certain situations may justify the use of the drug despite its
afer drugs cannot be used or are ineﬀective for treatment of serious
alities or there is evidence in humans of foetal risk, or both, and the
Table 2 Summary of pregnancy risk categorization of non-US-FDA approved medications.
Generic name (brand
name$)
Therapeutic category Proposed pregnancy
risk category
Detailed pregnancy risk information
Aceclofenac (Airtal) Non-steroidal anti-inﬂammatory
drug (NSAID)
C No human data were found
Animal studies indicate that there was no evidence of
teratogenicity in rats although the systemic exposure was
low. In rabbits, treatment with aceclofenac (10 mg/kg/
day) resulted in a series of morphological changes in
some foetuses. In general, the regular use of NSAIDs
during the last trimester of pregnancy may decrease
uterine tone and contraction. NSAIDs use may also
result in premature closure of the foetal ductus arteriosus
in utero and possibly persistent pulmonary hypertension
of the new born, delay onset and increase duration of
labour (Saudi Food and Drug Authority. SPDI, 2008;
EMC, MHRA, BNF)
FDA pregnancy risk category for other NSAIDs is (C)
and (D) in third trimester (Briggs et al., 2005)
Acematacin (Rantudil) NSAID C No human data were found
Animal reproduction studies do not provide reassurance
regarding the lack of reproductive toxicity/
teratogenicity. Due to maternal toxicity, the studies were
conducted at doses below the therapeutic dose (EMC,
BNF)
FDA pregnancy risk category for other NSAIDs is (C)
and (D) in 3rd trimester (Briggs et al., 2005)
Acipimox (Olbetam) Antilipemic C No human data were found
There is no evidence from the animal studies that
acipimox is teratogenic. However, a higher incidence of
immature and underweight foetuses was seen in pregnant
animals given higher doses of acipimox. This eﬀect may
be due to maternal toxicity (EMC, BNF)
Aescin (Reparil) Haemorrhoid preparation C No human or animal data found
Alverine (Spasmonal) Antispasmodic C No human data were found
Evidence of safety in animal studies is limited; however,
no teratogenic eﬀects have been reported (MHRA)
Ambroxol (Ambolar,
Riabroxol, Riabroxol,
Ambrosia)
Mucolytic C No human data were found
Ambroxol is a metabolite of bromhexine; see bromhexine
Amisulpride (Solian) Dopamine antagonist C No human data were found
Animal reproductive studies did not show reproductive
toxicity or teratogenicity (BNF)
Atosiban (Tractocil) Tocolytic C No animal data found
Human embryo-foetal toxicity studies have not shown
toxic eﬀects. No studies were performed that covered
early embryonic development (Saudi Food and Drug
Authority. SPDI, 2008; EMC)
Azapropazone
(Prolixan)
NSAID C No human or animal data found
FDA pregnancy risk category for other NSAIDs is (C)
and (D) in 3rd (Briggs et al., 2005)
Azintamide (Oragallin) Choleretic C No animal or human data were found
Barnidipine (Vasexten) Calcium channel
Blocker;
Dihydropyridine
Derivative
C No animal or human data were found
Betahistine (Betaserc) Histamine (H1) agonist B No human data were found
Animal studies using high doses betahistine did not show
teratogenic eﬀects (EMC, MHRA, Lexi–Comp Online,
ADEC)
Bezaﬁbrate (Bezalip) Antilipemic; ﬁbric acid C No human data were found
Animal studies showed that embryo toxicity has
occurred at toxic doses (EMC, BNF, Lexi–Comp Online,
DRUGDEX)
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Table 2 (continued)
Generic name (brand
name$)
Therapeutic category Proposed
pregnancy risk
category
Detailed pregnancy risk information
Bromazepam
(Lexotanil)
Benzodiazepine D In human, one study reported in abstract, found an association
between maternal use of bromazepam and urinary system
abnormalities in data from birth defects registry. However, this
association was based on ﬁndings from only ﬁve cases and will
require further investigation and documentation. Bromazepam
crosses placenta. Oral clefts reported, however; more recent
data do not support an association between drug and oral
clefts. Inguinal hernia, cardiac defects, spina biﬁda,
dysmorphic facial features, skeletal defects, and multiple other
malformations were reported. Hypotonia and withdrawal
symptoms reported following use near time of delivery. As
with other benzodiazepines, symptoms of neonatal withdrawal
have been reported in a neonate whose mother was treated
with bromazepam and other drugs during the third trimester
Animal studies of this agent were negative in mammalian-
based genotoxicity testing. In pregnant rats given up to 30 mg
per kg per day, a decrease in pup weight and an increase in
perinatal deaths were associated with maternal sedation (Lexi–
Comp Online, DRUGDEX, ADEC)
Bromhexine
(Mucofree)
Mucolytic C No human data were found. Ambroxol (is a metabolite of
bromhexine). Teratogenicity and reproductive toxicity testing
of ambroxol at high doses in rats and rabbits has been
reassuring (DRUGDEX, ADEC).
Butropium (Bisolvon) Anticholinergic C No human data were found
Pregnant mice and rats were administered maximum oral doses
of 500 mg per kg per day and maximum intraperitoneal doses
of 40 mg per kg. The dams evidenced autonomic reactions. No
increase in foetal death or congenital defects was found in
foetuses exposed during active organogenesis (DRUGDEX)
Carbetapentane
(Toclase)
Cough suppressant C No animal or human data were found (Lexi–Comp Online,
DRUGDEX)
Carbimazole (Neo-
Mercazole)
Antithyroid agent; thioamide D Carbimazole is rapidly and completely metabolized to
methimazole
Human data showed that 15 cases of scalp defects have been
reported in children born to women treated with carbimazole.
However, the causal relationship has not been proven. There is
evidence that carbimazole use in pregnancy may lead to a
distinct phenotype or syndrome. One case report described an
infant born with choanal atresia following ﬁrst trimester
exposure to carbimazole. There have been 5 other similar
reports, including choanal atresia and other birth defects.
Anomalies noted in the literature include choanal atresia,
oesophageal atresia, athelia/hypothelia, developmental delay,
hearing loss, and dysmorphic facial features. The facial
features include broad nasal bridge, short upslanting palpebral
ﬁssures, prominent epicanthal folds, hypoplastic alae nasi, and
small ears (Saudi Food and Drug Authority. SPDI, 2008;
EMC, Briggs et al., 2005; Foulds et al., 2005)
Carbocysteine
(Bronchobos)
Mucolytic C No human data were found
No harmful eﬀects were noted with maximum daily doses of
500 mg and 250 mg per kg in animal studies conducted on
pregnant rats and rabbits during active organogenesis. In
another study, carbocysteine was given by mouth to rats on
days 17–21 of gestation and for 21 days after birth. No adverse
eﬀects on postnatal development were found (DRUGDEX)
Cilazapril (Inhibace) Angiotensin-converting enzyme
inhibitor (ACEI)
C No animal or human data were found
FDA pregnancy risk category for other ACE inhibitors is (C)
and (D) in 2nd and 3rd trimesters (Briggs et al., 2005)
(continued on next page)
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Table 2 (continued)
Generic name (brand
name$)
Therapeutic category Proposed
pregnancy risk
category
Detailed pregnancy risk information
Cinnarizine (Stugeron) Antihistamine C In human a single case of ectromelia has been reported after
intrauterine exposure to this agent; however, it is not possible to
implicate cinnarizine as the cause of the malformation in this single
case. The calcium channel blocking eﬀect of cinnarizine may result in
impairment of uterine contractility; however, an in vitro study of
human myometrium showed such an eﬀect only at high
concentrations
Animal studies showed that cinnarizine did not increase the incidence
of congenital anomalies in guinea pigs (Saudi Food and Drug
Authority. SPDI, 2008; DRUGDEX). FDA pregnancy risk
category for other antihistamine is (B) (Briggs et al., 2005)
Ciproﬁbrate
(Modalim)
Antilipemic; ﬁbric acid C No human data were found
Animal studies, found no teratogenic eﬀects in rats. Postnatal eﬀects
such as thrombosis and increased liver size were found
(DRUGDEX)
Clobutinol* (Orcinol) Antitussive C No human data were found
Animal studies in rats and mice showed no foetal or postnatal eﬀects.
Treatment was from the 8th through the 14th day with oral doses up
to 75 mg per kg per day (DRUGDEX)
Clopenthixol,
zuclopenthixol
(Clopixol)
Antipsychotic agent C No human data were found
Animal studies did not show any evidence that zuclopenthixol causes
an increased incidence of foetal defects (EMC, Lexi–Comp Online)
Cyproterone
(Androcur)
Antiandrogen D Animal studies showed that cyproterone acetate in high doses only is
associated with congenital malformations. There is a possibility of
abnormal sexual diﬀerentiation of the foetus or other teratogenic
eﬀects. Feminization of male foetuses has also been described in
animals after exposure to the drug during sexual diﬀerentiation
In humans, the limited data available do not suggest a signiﬁcant risk
of teratogenicity or abnormal sexual diﬀerentiation. Healthy male
and female infants have been delivered after inadvertent use of low
doses and relatively high doses (50–100 mg daily) of cyproterone
acetate combined with ethinyl estradiol during early pregnancy (BNF,
Lexi–Comp Online, DRUGDEX, ADEC)
Deferiprone
(Ferriprox)
Iron chelating agent C No animal or human data were found
FDA pregnancy risk category for deferasirox another iron chelating
agent is (B) (Briggs et al., 2005)
Dibekacin (Dibekacin)
Sulphate
Antimicrobial; aminoglycoside C No animal or human data were found
FDA pregnancy risk category for other aminoglycosides (i.e.
gentamicin) is (D) (Briggs et al., 2005)
Diloxanide (Furamide) Amebicide C No animal or human data were found
Dimeﬂine (Remeﬂin) Respiratory stimulant C No animal or human data were found
Diosmin (Daﬂon) Haemorrhoid preparation;
ﬂavonoid extract
A In an open study, diosmin/hesperidin 2–3 g for 3–4 days was eﬀective,
acceptable and safe in the treatment of haemorrhoids in pregnancy
(Buckshee et al., 1997)
Animal studies have not demonstrated any teratogenic eﬀect and no
harmful eﬀect on the foetus have been reported (Saudi Food and
Drug Authority. SPDI, 2008; DRUGDEX)
Disodium clodronate
(Bonefos)
Bisphosphonate C No human data were found
In general, bisphosphonates have been shown to cross the placenta
and cause embryo/foetal eﬀects in animals (EMC, Lexi–Comp
Online)
Distigmine (Ubretid) Cholinesterase inhibitor C No animal or human data were found
FDA pregnancy risk category for other cholinesterase inhibitors is
(B) for pyridostigmine while it is (C) for neostigmine and
physostigmine (Briggs et al., 2005)
Domperidone
(Dompy, Motilium)
Dopamine antagonist B No human data were found
Animal studies have used doses 100 times greater than that
recommended for humans without any teratogenic eﬀects (EMC,
BNF, Lexi–Comp Online, DRUGDEX, ADEC, Briggs et al., 2005)
FDA pregnancy risk category for domperidone is (C) (Briggs et al.,
2005)
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Table 2 (continued)
Generic name (brand
name$)
Therapeutic category Proposed
pregnancy risk
category
Detailed pregnancy risk information
Dothiepin (Prothiaden) Antidepressant; tricyclic D Human data reported withdrawal symptoms in infants born to
mothers on long-term use of tricyclic antidepressant for migraine has
been associated with teratogenic eﬀects; however, a clear causal
relationship has not been established
In rats, evidence of interference with central monoamine
neurotransmission has been reported with tricyclic antidepressant
use (EMC, ADEC)
Ethamsylate (Aglumin) Haemostatic C Animal studies revealed no teratogenic eﬀect
There is inadequate evidence of safety in human. It crosses the
human placenta (EMC, DRUGDEX)
Etofamide (Kitnos) Amoebicide; dichloroacetamide
derivative
C No animal or human data were found
Etoﬁbrate (Lipo-Merz,
Lipomerse)
Cloﬁbrate derivative and
nicotinic acid derivative
C No animal or human data were found
Etoricoxib (Arcoxia) NSAID; COX-2 Selective C No human data were found
Animal studies have shown reproductive toxicity. However;
etoricoxib was not teratogenic in reproductive toxicity studies
conducted in rats at 15 mg/kg/day (this represents approximately 1.5
times the daily human dose based on systemic exposure). In rabbits,
a treatment related increase in cardiovascular malformations was
observed at exposure levels below the clinical exposure at the daily
human dose (90 mg). However, no external or skeletal foetal
malformations were observed (Saudi Food and Drug Authority.
SPDI, 2008; EMC, MHRA, BNF)
FDA pregnancy risk category for other NSAIDs is (C) and (D) in
3rd trimester (Briggs et al., 2005)
Flucloxacillin
(Fluxapen)
Antimicrobial; penicillin B No evidence of teratogenic eﬀect in animals or humans (EMC,
ADEC)
Flunarizine (Sibelium) Antihistamine, calcium channel
blocker, piperazine class
B No human or animal data found
Fluocortolone
(Ultralan)
Adrenal glucocorticoid C No human data were found
In animal studies, mice foetuses had increased number of cleft
palates (DRUGDEX, ADEC)
Flupenthixol,
Flupentixol (Fluanxol)
Dopamine antagonist D Crosses the human placenta. Human pregnancy outcomes have been
reported to be normal with ﬂupenthixol exposure, but the number of
reported cases is small. Other dopamine antagonist may cause
menstrual disturbances, possibly mediated by an increased prolactin
level (Saudi Food and Drug Authority. SPDI, 2008; Lexi–Comp
Online, DRUGDEX, ADEC)
Fusidic acid (Fucidin) Antimicrobial C Inadequate evidence in human. Systemic fusidic acid crosses the
human placenta
Animal studies suggest that fusidic acid is not teratogenic (EMC,
Lexi–Comp Online, DRUGDEX, Middle East Drug Index,
ADEC)
Hexoprenaline
(Ipradol)
Beta-2 adrenergic agonist;
tocolytic
C Human data showed no signs of pathological development or
myocardial dysfunction in children whom mothers received it as
tocolytic in late trimester. However, one case of supra-ventricular
arrhythmia was reported (D’Hooghe and Odendaal, 1991;
Trittenwein et al., 1986; Wilk, 1985)
Animal studies showed no evidence of teratogenicity in rats but an
increase in stillborn with no dysmorphogenic eﬀects in rabbit was
seen (Saudi Food and Drug Authority. SPDI, 2008; DRUGDEX)
FDA pregnancy risk category for similar drug (terbutaline) is (B)
(Briggs et al., 2005)
Homochlorcyclizine
(Homoclomin)
Piperazine derivative; sedating
antihistamine; antimuscarinic
C No animal or human data were found
Hymecromone
(Bilicante)
Choleretic; biliary
antispasmodic
C No animal or human data were found
Ifenprodil (Vadilex) Vasodilator, with alpha-
adrenoceptor blocking
properties
C No adverse eﬀects observed in animal species (MHRA)
(continued on next page)
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Table 2 (continued)
Generic name (brand
name$)
Therapeutic category Proposed
pregnancy risk
category
Detailed pregnancy risk information
Imidapril (Tanatril) ACEI C No human data were found
Animal studies showed no increase in defects in doses up to 1500 mg
per kg but there was a reduction in the term female foetuses’ weight.
Rabbits received up to 1 mg per kg during organogenesis had no
adverse foetal eﬀects. The studies in rats treated before fertilization
did not reveal any adverse eﬀects (Saudi Food and Drug Authority.
SPDI, 2008; DRUGDEX)
FDA pregnancy risk category for ACE inhibitors is (C) and (D) in
2nd and 3rd trimesters (Briggs et al., 2005)
Iobitridol, Tobitridol
(Xenetix)
Non-ionic iodinated
radiographic agent
C Transplacental passage was not established in one animal study
(Bourrinet et al., 1995)
Josamycin (Josaxin) Antimicrobial; macrolide B Human data showed no signiﬁcant foetal risk (Saudi Food and Drug
Authority. SPDI, 2008; DRUGDEX)
FDA pregnancy risk category for other macrolides is (B) for
azithromycin and erythromycin while it is (C) for clarithromycin
(Briggs et al., 2005)
Lercanidipine
(Lercapid, Zanidip)
Calcium channel blocker;
dihydropyridine derivative
C No human data were found
No teratogenic eﬀect in animals (rat and rabbit) identiﬁed. Other
dihydropyridine compounds have been found teratogenic in animals
(Saudi Food and Drug Authority. SPDI, 2008; EMC)
Lisuride (Dopergin)
(Lysuride)
Anti-Parkinson’s agent; ergot
derivative
B No human data were found
In animal studies, no teratogenic eﬀect was seen (DRUGDEX)
Lornoxicam (Xefo) NSAID C No human data were found
In animal studies, no teratogenicity was seen in rats (Saudi Food and
Drug Authority. SPDI, 2008; EMC, MHRA, BNF, DRUGDEX).
FDA pregnancy risk category for other NSAIDs is (C) and (D) in
3rd trimester (Briggs et al., 2005)
Loxoprofen (Roxonin) NSAID C No animal or human data were found
FDA pregnancy risk category for other NSAIDs is (C) and (D) in
3rd trimester (Briggs et al., 2005).
Lynestrenol
(Orgametril)
Progesterone, structurally
related to norethisterone
D No human data were found. Animal studies showed reduction of the
length of urovaginal septum in female rat foetuses (Saudi Food and
Drug Authority. SPDI, 2008; DRUGDEX)
FDA pregnancy risk category for norethisterone in the ﬁrst trimester
is (X) (Briggs et al., 2005)
Menfegol
(Neosampoon)
Spermicidal agent C No animal or human data were found
Mephenesin,
Mefenesin
(Decontractyl)
Skeletal muscle relaxant,
centrally acting
C No animal or human data were found
Mesterolone (Proviron,
Provironum)
Androgenic steroid D No animal or human data were found
Androgenic steroid use by pregnant women may lead to
pseudohermaphroditism or growth retardation of the female foetus.
Female foetal virilisation after maternal use of testosterone or
methyltestosterone during pregnancy was reported (EMC,
DRUGDEX)
FDA pregnancy risk category for testosterone is (X) (Briggs et al.,
2005)
Midecamycin
(Medemycin)
Antimicrobial; macrolide C No animal or human data were found
FDA pregnancy risk category for other macrolides is (B) for
azithromycin and erythromycin while it is (C) for clarithromycin
(Briggs et al., 2005)
Molgramostim
(Leucomax)
Colony stimulating factor
(CSFs)
C No human data were found. Animal studies have shown
reproductive toxicity (SPDI, 2008)
Moxonidine
(Physiotens)
Centrally acting
antihypertensive, structurally
related to clonidine
C No animal or human data were found
Nefopam (Painstop) Non-narcotic analgesic B No human data were found
Animal studies have not demonstrated any teratogenic eﬀect at doses
up to 80 mg per kg per day (EMC, Lexi–Comp Online,
DRUGDEX)
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Generic name (brand
name$)
Therapeutic category Proposed
pregnancy risk
category
Detailed pregnancy risk information
Nicergoline (Sermion) Ergot derivative C No animal or human data were found
Nitrazepam (Dumolid,
Mogadon)
Benzodiazepine C Limited human case reports and series do not suggest that human
therapeutic use increases the risk of congenital malformations
(EMC, Lexi–Comp Online)
In animals it produced adverse eﬀects on rat but not mice
development, probably related to metabolic activation in rats
(DRUGDEX, ADEC)
FDA pregnancy risk category for other benzodiazepine is D (Briggs
et al., 2005)
Ornidazole (Tiberal) Antiprotozoal B In humans, a pharmacokinetic study in small number of patients (5)
who were given ornidazole showed no increased in teratogenicity
(Bourget et al., 1995)
No animal data were found
Oxethazaine, oxythazaine
(Mucaine Strocain)
Local anaesthetic;
anticholinergic
A3rd A double blind comparative study of oxethazaine and placebo in 50
patients with symptoms of heartburn during late pregnancy showed
no adverse eﬀects on pregnancy outcomes (Kovacs et al., 1990)
No animal data were found
Pinaverium bromide
(Dicete)
Calcium channel blocker C A letter to the editor reported 10 pregnant women who inadvertently
took pinaverium due to prescription errors. Only one pregnancy
miscarriage occurred and the remainder resulted in normal babies
(DRUGDEX, Einarson et al., 1999)
No animal data were found
Piracetam (Nootropil) Antipsychotic; nootropic B No human data were found
In animal studies, piracetam was not teratogenic at the maximal
tested dose of 2.7 g per kg per day for the rabbit and 4.8 g per kg per
day for rats and mice. Piracetam readily crosses placenta (EMC)
Piribedil (Trivastal) Anti-Parkinson’s agent;
dopamine agonist
C No animal or human data were found
Pizotifen (Appi- D,
Mosegor, Zofen)
Serotonin and histamine
antagonist
C No human data were found
In animals, there was a decrease in foetal weight at all doses given to
pregnant rats but with no increase in congenital malformations. No
mention was made of maternal toxicity. This study does not provide
an adequate assessment of potential reproductive eﬀects (Saudi Food
and Drug Authority. SPDI, 2008; DRUGDEX)
Priﬁnium bromide
(Riabal)
Anticholinergic;
antispasmodic
B No human data were found
In animal studies, administration to pregnant rats, mice, and rabbits
did not result in adverse foetal eﬀects (DRUGDEX)
Pyridinol-carbamate
(Colesterinex)
Anti-atherosclerotic agent C No animal or human data were found
Quinagolide (Norpolac) Dopamine (D2) agonist C No animal or human data were found
Reboxetine methane-
sulphone (Edronax)
Norepinephrine selective
reuptake inhibitor
C No animal or human data were found
Rilmenidine dihydrogen
phosphate (Hyperium)
Alpha2-adrenergic
receptor agonist
C No animal or human data were found
FDA pregnancy risk category for other Alpha2-adrenergic receptor
agonists is (B) for methyldopa and guanfacine while it is (C) for
clonidine and guanabenz (Briggs et al., 2005)
Roxithromycin (Ruxid,
Romac, Roxamed)
Antimicrobial; macrolide A In 9 reported cases, roxithromycin did not show any teratogenicity
Roxithromycin does not appear to be a major teratogen in a
prospective study where 183 women with ﬁrst trimester exposure to
roxithromycin were followed through delivery and no adverse
developmental eﬀects were identiﬁed. Studies in animals have not
shown evidence of an increased risk of foetal defects (DRUGDEX,
Czeizel et al., 2000; Tellem et al., 2005; Chun et al., 2006; Paulus
et al., 2005)
FDA pregnancy risk category for other macrolides is (B) for
Azithromycin and erythromycin while it is (C) for clarithromycin
(Briggs et al., 2005)
Sodium ioxitalamate
(Telebrix)
Iodinated radiographic
agent
C No animal or human data were found
(continued on next page)
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Generic name (brand
name$)
Therapeutic category Proposed
pregnancy risk
category
Detailed pregnancy risk information
Sodium-Stibogluconate
(Pentosam)
Antimicrobial agent;
miscellaneous
D In one human study, there were 13 (57%) spontaneous abortions in
the sodium stibogluconate monotherapy group and none in either of
the other two groups (Ambisome and sodium stibogluconate and
ambisome alone) (Mueller et al., 2006)
No animal data were found
Sulpiride (Dogmatil,
Genprid)
Antipsychotic agents C In pregnant women who took sulpiride; the drug concentrations in
maternal plasma in late pregnancy and postnatally and in umbilical
cords were almost the same, which mean they were freely transferred
from mothers to babies
In animals, administration of sulpiride to pregnant rats was
associated with increased risk of foetal hyperprolactinemia and
increased growth (DRUGDEX, Yoshida and Yamashita, 2003)
Teicoplanin (Targocid) Antimicrobial; miscellaneous C No human data were found
Animal studies have not shown teratogenic eﬀect (DRUGDEX)
Tenoxicam (Tenox) NSAID C When studied in a small group of women who were undergoing
caesarean section, a single intravenous 20-mg dose of tenoxicam
given 10 min before induction of anaesthesia reduced postoperative
need for pain medication without notable adverse eﬀects on mother
or foetus (DRUGDEX, Elhakim and Naﬁe, 1995)
No increase in congenital anomalies when tested in mice, rats, and
rabbits; however, an increase in embryo death was seen in rabbits at
the top dose used (32 mg per kg per day). The highest doses used in
mice and rats were 4.8 and 12.0 mg per kg per day; respectively.
FDA pregnancy risk category for other NSAIDs is (C) and (D) in
3rd trimesters (Briggs et al., 2005)
Thiamphenicol
(Thiophenicol)
Antimicrobial; broad
Spectrum
C No human data were found. In one animal series, the frequency of
congenital anomalies was no greater than expected among the
oﬀspring of mice or rats treated during pregnancy with
thiamphenicol in doses; respectively, 1–33 and 1–3 times those used
clinically. Foetal loss occurred at the higher doses that were toxic to
the mothers. In contrast, another study showed an increased
frequency of skeletal malformations among the oﬀspring of rats
treated with double the usual human dose very early in pregnancy
(DRUGDEX).
Tianeptine (Stablon) Antidepressant; serotonin
reuptake facilitator
C No animal or human data were found
Tiapride, Tiapridum
(Tiapridal)
Dopamine (D2) antagonist C No human data were found
One group studied tiapride in rats using up to 500 mg per kg doses
during organogenesis or from day 17 until 3 weeks after birth. No
teratogenicity was found but there was slight retardation of
postnatal growth (DRUGDEX)
Tiaprofenic acid (Surgam) NSAID C No human data were found
No teratogenic eﬀects were found during animal studies but
parturition was delayed and prolonged (Saudi Food and Drug
Authority. SPDI, 2008; EMC, MHRA, BNF, DRUGDEX)
FDA pregnancy risk category for other NSAIDs is (C) and (D) in
3rd. trimester (Briggs et al., 2005)
Tibolone (Livial) Oestrogen and progestin
combination
C No human data were found
Studies in animals have shown reproductive toxicity (EMC)
Trimebutine (Debridat) 5-Hydroxytryptamine
(5HT3) receptor antagonist
C No human data were found
No adverse eﬀect on postnatal and foetuses in animals (Lexi–Comp
Online)
FDA pregnancy risk category for other 5-HT3 receptor antagonists
is (B) (Briggs et al., 2005)
Trimetazidine (Vastarel) Cardiovascular agent C No animal or human data were found
Tropisetron (Navoban) Serotonin antagonist C No human data were found
Animal studies reported foetal toxicity (SPDI, 2008)
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Generic name (brand
name$)
Therapeutic category Proposed
pregnancy risk
category
Detailed pregnancy risk information
Troxerutin (Venoruton) Antioxidant B Several controlled trials in pregnant women have found no adverse
eﬀects on pregnancy or birth outcomes; however, detailed evaluation
for newborn abnormalities was inadequate (DRUGDEX). An
uncontrolled trial found that high doses of rutosides (up to 3 g per
day) used to treat haemorrhoids were well-tolerated during
pregnancy and postpartum (EMC). A population-based case-control
study of isolated ocular coloboma found an association with
maternal exposure to hydroxyethylrutoside (EMC). Of 46 aﬀected
cases, six (13%) had been born to women who had used this agent
[adjusted OR 5.4 (95%CI 2.2–12.9)]. Five of the six had medically
documented exposures with apparent use throughout pregnancy
(MHRA). In animals, administration of troxerutin to pregnant rats
did not produce an increase in anomalies in the oﬀspring
(DRUGDEX)
Vigabatrin (Sabril) Anticonvulsant;
miscellaneous
D Two cases of human congenital anomalies were reported.
Increased congenital anomalies seen in animals as well (EMC, BNF,
DRUGDEX, Abdulrazzaq et al., 1997)
Viloxazine (Vivalan) Antidepressant; bicyclic C No animal or human data were found
Vindesine (Eldisine) Antineoplastic agent; Vinca
alkaloid
D No human data were found
Teratogenic in animals especially during 1st trimester (EMC)
$ Brands registered in the Saudi National Formulary (SNF) October 2007.
* Currently not available in SNF June 2010.
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thomsonhc.com), Middle East Drug Index (CCMMiddle East
s.a.r.l, Dec 2007–Nov 2008), Australian Drug Evaluation Com-
mittee’s (ADEC) Category (Commonwealth of Australia, 1999.
Available at: http://www.tga.gov.au/docs/html/medpreg.htm),
AReferenceGuide to Foetal andNeonatal Risk: Drugs in Preg-
nancy andLactation (Briggs et al., 2005), Pubmed/Medline. The
Pubmed and Medline were searched from 1960 to December
2008 with no language restrictions using the following search
terms: drug name, pregnancy, functional or anatomical birth de-
fects, embryocidal effect, and teratogenicity. A single risk cate-
gorywas assigned to eachmedication according to the evaluated
data.More than one risk level was assigned formedications with
a different risk at different trimesters. Furthermore, the US-
FDA category for similar medication(s) was added whenever
it differed from the assigned category designated by the authors.
Disagreements were resolved by consensus. Foetal risk assess-
ment for all medications was summarized according to the avail-
able data. All 93 medication package inserts were reviewed to
identify whether the manufacturer has formal pregnancy pre-
vention risk-management strategies to direct clinicians and/or
patients (e.g., frequency of pregnancy testing or number and
type of contraception methods).
We attempted to summarize the evidence from animal as
well as human data (case reports, case series, pregnancy regis-
tries or post-marketing surveillance) pertaining to the identi-
ﬁed effect on pregnancy outcomes for each of the included
medications.
3. Results
The literature search results for 93 medications are summa-
rized in Table 2. Sixty-nine medications (73%) were judgedby the authors to be category risk C. Of these the risk catego-
rization of 32 medications was based only on animal studies.
Eight medications had published human data and 29 medica-
tions had neither human nor animal data.
Ten medications were assigned category risk D (10.6%).
Medications classiﬁed as category risk D belong to the follow-
ing groups: benzodiazepines, anti-androgens, androgen ste-
roids, anti-thyroids, antimicrobials, dopamine antagonists,
antidepressants, anticonvulsants, oestrogen and progesterone
derivatives, antineoplastics, and analgesic agents. Twelve med-
ications (12.7%) were assigned category risk B including hista-
mine agonists, haemorrhoid preparations, antimicrobials,
antihistamines, ergot derivatives, antiprotozoals, antipsychot-
ics, dopamine agonists, antioxidants and two anticholinergic
medications. Roxithromycin, oxethazaine, and diosmin were
the only medications assigned category risk A based on the
available evidence.
Among the 93 medications’ package inserts that were re-
viewed to identify any pregnancy prevention risk management
strategies recommended by the manufacturer, 7 medications
had no information on the use during pregnancy in the
package inserts. None of the 93 medications had a formal
pregnancy risk management system. Ten medications (bezaﬁ-
brate, bromazepam, bromhexine ‘‘in the ﬁrst trimester’’, clo-
butinol, cyproterone, deferiprone, quinagolide, sodium-
stibogluconate, tianeptine, tiaprofenic acid ‘‘in the ﬁrst trimes-
ter’’) had clear statements indicating that women should be
counselled to take contraceptive measures. The statements also
indicated that women should be advised to immediately stop
taking the medication should they become pregnant or plan
to become pregnant. The remaining medications had general
statements that women should consult their physician or phar-
macist if they are pregnant or planning to become pregnant.
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The decision to prescribe a medication during pregnancy in-
volves multiple factors that include molecular weight of the
drug, whether the drug crosses the placenta, pregnancy trimes-
ter (gestational age), and the necessity to use the prescribed
medication during pregnancy. Usually, a beneﬁt of using the
medication against any possible risk to the mother or the foe-
tus is undertaken during this process. A thorough understand-
ing of these beneﬁts and risks is mandatory before prescribing.
Current regulatory requirements for assessing the risk of
teratogenicity of new medications do not mandate human
studies. This is understandable as it would be unethical to in-
clude pregnant women who are typically excluded from all
stages of preapproval clinical trials. The only available two
methods for assessing teratogenicity of drugs in humans are
case series and pregnancy registries (e.g., Pregnancy Exposure
Registries available in Women’s Health Research).
Currently, four countries have developed a pregnancy risk
categorization for marketed pharmaceuticals. Australia, Ger-
many, Sweden, and the United States have their own preg-
nancy risk categorization which is mainly based on the
availability of evidence that supports safety or teratogenicity
during pregnancy. In 1979, the US-FDA developed a classiﬁ-
cation of foetal risks for marketed medications (Table 1). This
was based on a similar system that was introduced in Sweden
one year earlier. The currently used US-FDA pregnancy risk
categorization has been criticized by many clinicians and
researchers as insufﬁcient to determine drug safety accurately
during pregnancy. The Teratology Society (http://www.tera-
tology.org) has called for a change in pregnancy labelling for
medications as the current classiﬁcation does not adequately
communicate risk of reproductive and developmental toxicity.
In addition, the categories do not discriminate among poten-
tial developmental adverse effects based on severity, frequency,
or type. They do not adequately address the full range of po-
tential developmental drug effects including foetal death,
structural malformations, alterations in foetal growth, and
functional deﬁcits (Buhimschi and Weiner, 2009; Public Af-
fairs Committee of the Teratology Society, 2007). In 2008,
the US-FDA proposed major revisions to the labelling of pre-
scription drugs (including biological products) to provide bet-
ter information about the effects of medications used during
pregnancy and breastfeeding (FDA News). Worth mentioning,
that it has been almost three years since the publication of the
initial proposal and until now it has not been ﬁnalized. Until
the time of writing this manuscript the US-FDA still uses
the current pregnancy risk categorization for newly approved
medications and continues to change the pregnancy risk levels
assigned to certain approved medication.
There is scant information on pregnancy outcomes of many
of the non-US-FDA approved medications. Often, the safety
of similar drugs cannot be determined until they have been
widely used. The medications reviewed in this study are not
marketed in the United States; therefore, they are not assigned
a pregnancy risk categorization by US-FDA. In addition, there
is inadequate information on teratogenicity of currently ap-
proved drugs in the US to determine risk-beneﬁt ratio before
prescribing (Lo and Friedman, 2002). Moreover, despite the
fact that the currently used categorization system by the US-
FDA does not accurately determine foetal safety, and due tothe lack of a better locally or internationally endorsed system
by regulatory bodies in the country we believe that the US-
FDA pregnancy risk categorization is the most commonly
used system by clinicians in practice in Saudi Arabia.
In this review, we attempted to categorize all non-US-FDA
approved medications in Saudi Arabia up until October 2007
according to the non-US-FDA pregnancy risk categorization
system based on the current available evidence. We also sum-
marized the evidence from animal and human data (case re-
ports, case series, pregnancy registries or post marketing
surveillance) pertaining to their effect on pregnancy outcomes
for each of these medications. To our knowledge, this is the
ﬁrst attempt to assess and analyse the foetal risk for previously
uncategorized non-FDA approved medications.
The importance of this analysis stems from the fact that
despite the criticism the US-FDA classiﬁcation has received,
clinicians from different countries still depend on this classiﬁ-
cation almost exclusively when prescribing, discontinuing, or
substituting medications during pregnancy (Buhimschi and
Weiner, 2009; Public Affairs Committee of the Teratology
Society, 2007). Furthermore, this assessment could be used
as a starting point for clinicians in other countries such as
Europe, Canada and Australia to evaluate the pregnancy risk
of non-US-FDA approved medications used by their patients.
Our results showed that the pregnancy risk categoryﬁgures as-
signed in this review were comparable to the ﬁgures currently as-
signed by the US-FDA to marketed drugs based on previously
published reports. Themajority of the reviewedmedicationswere
assigned category C (73%) and this approximates the US-FDA
data in which about 60% of the medications belong to this cate-
gory (Uhl et al., 2002). Since the majority of medications have
data on their teratogenicity only in animals but not humans or
they have no data whatsoever, this was expected. This ﬁnding
has been cited and discussed by previous investigators and was
attributed to less active post-marketing surveillance (Adam
et al., 2011). It is of note that similarity between the two ﬁgures
is not meant to validate our proposed classiﬁcation.
When reviewing the package inserts of these medications,
inconsistencies in deﬁning the foetal risk for speciﬁc medica-
tion was apparent. In addition, only few drugs had speciﬁc
pregnancy prevention risk-management strategies to direct
the clinician and/or patient. This analysis demonstrates the ur-
gent need for both consistency in the description of the foetal
risk within the medication package insert and in the recom-
mendations by the manufacturer for speciﬁc and formal preg-
nancy prevention risk-management programs.
The main limitation of this analysis is that it comes from an
independent group which did not have access to drug manu-
facturers’ on-ﬁle data. We also performed only Medline search
and did not include EMBASE and other databases for primary
literature search.
5. Conclusion
Our results showed comparable ﬁgures of pregnancy risk
category to the currently US-FDA approved medications
based on available data. Inconsistencies in deﬁning and
reporting the foetal risk category/assessment among different
drug regulatory authorities would create confusion and affect
the prescribing decision pattern. We believe that standardiza-
tion and inclusion of this information in medications
Assessment of foetal risk associated with 93 non-US-FDA approved medications during pregnancy 299package inserts are extremely important to all health care
practitioners.
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